Sort
10,766 grants matching “checkpoint inhibitor”
Project 1: Remodeling Chromatin and the Tumor Microenvironment: Direct Oncogenesis and Therapeutic Targeting
$345,406David E Fisher · Massachusetts General Hospital · P01 · FY2019 · CA
[Jang R01AG058560 transfer] Role of BubR1 as a juvenile protective factor in hippocampal aging
$345,400Mi-Hyeon Jang · Rbhs-Robert Wood Johnson Medical School · R01 · FY2022 · AG
Lynch Vaccine
$345,292Steven Monroe Lipkin · Weill Medical Coll Of Cornell Univ · U54 · FY2024 · CA
Improvement of cellular immunotherapy during dysbiosis- Resubmission
$345,287Ruud P.m. Dings · Univ Of Arkansas For Med Scis · R01 · FY2021 · CA
Optimizing Response to Immune Checkpoint Inhibitor Therapy for Breast Cancer: A Role for Inhibitors of the PI3K pathway
$345,281Ann Richmond · Vanderbilt University · R01 · FY2024 · CA
Optimizing systemic immunotherapy for personalized brain metastasis treatment
$345,270Michael Lim · Stanford University · U54 · FY2024 · CA
Novel focused ultrasound enhanced calreticulin-nanoparticle for immune primed melanoma immunotherapy
$345,260Ashish Ranjan · Oklahoma State University Stillwater · R37 · FY2022 · CA
Targeting CDK4 and CDK6 kinases in breast cancer development
$345,237Piotr Sicinski · Dana-Farber Cancer Inst · P01 · FY2024 · CA
Lung cancer prevention and treatment by targeting ALDH1 and CD44 expressing putative lung cancer stem cells
$345,230Fekadu Kassie · University Of Minnesota · R01 · FY2022 · CA
A novel therapeutic strategy to eradicate breast cancer through Hsp90 inhibition and reduced immune tolerance
$345,230Ahmed Chadli · Augusta University · R01 · FY2022 · CA
Lung cancer prevention and treatment by targeting ALDH1 and CD44 expressing putative lung cancer stem cells
$345,230Fekadu Kassie · University Of Minnesota · R01 · FY2023 · CA
A novel therapeutic strategy to eradicate breast cancer through Hsp90 inhibition and reduced immune tolerance
$345,230Ahmed Chadli · Augusta University · R01 · FY2023 · CA
Dual function of HSP70 in cytoprotection of tumor cells and generation of permissive microenvironment
$345,230Hasan Korkaya · Augusta University · R01 · FY2022 · CA
Targeting the vasculature to enhance anti-tumor immunity
$345,206Andrew Carl Dudley · University Of Virginia · R01 · FY2024 · CA
Hec1 Network as Molecular Therapeutic Targets
$345,129Wen-Hwa Lee · University Of California-Irvine · R01 · FY2014 · CA
A Phospholipid-Derived Nanotherapeutic Platform for Improved Colorectal Cancer Immunochemotherapy
$345,087Jianqin Lu · University Of Arizona · R01 · FY2023 · CA
Reprogramming of the stromal microenvironment in melanoma progression and therapeutic escape
$345,003Yuhang Zhang · University Of Cincinnati · R01 · FY2024 · CA
Protein Kinase Signaling and Cell Cycle Control
$344,968Michael B Yaffe · Massachusetts Institute Of Technology · R01 · FY2011 · ES
Project 3
$344,951John L. Cleveland · H. Lee Moffitt Cancer Ctr & Res Inst · P01 · FY2021 · CA
Estrogen receptor beta is a targetable melanoma tumor suppressor
$344,926Craig J Burd · Ohio State University · R01 · FY2023 · CA
Targeting CDK4 and CDK6 kinases in breast cancer development
$344,841Piotr Sicinski · Dana-Farber Cancer Inst · P01 · FY2022 · CA
Targeting CDK4 and CDK6 kinases in breast cancer development
$344,841Piotr Sicinski · Dana-Farber Cancer Inst · P01 · FY2023 · CA
Regulation of DNA replication kinetics by BRCA2 after DNA damage
$344,772Bing Xia · Rutgers Biomedical And Health Sciences · R01 · FY2025 · CA
Project 2: Re-directing the Sensitivity of Metastatic Castration-Resistant Prostate Cancer to Immunotherapy
$344,686Jennifer D Wu · Northwestern University At Chicago · P50 · FY2024 · CA
Targeting Wnt signaling in therapy-resistant ovarian cancer
$344,577Benjamin G Bitler · University Of Colorado Denver · R37 · FY2023 · CA